LOGIN  |  REGISTER
C4 Therapeutics

Jaguar Health (NASDAQ: JAGX) Stock Quote

Last Trade: US$1.33 0.04 2.71
Volume: 82,189
5-Day Change: -1.85%
YTD Change: 775.17%
Market Cap: US$12.240M

Latest News From Jaguar Health

SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo... Read More
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the recently completed analysis of the... Read More
Jaguar's commercial focus on cancer supportive care aims to use the best tools and techniques that assess the quality of life of cancer patients and survivors and deliver solutions to address these unmet needs - Commonly used tools and techniques fail to measure what patients are most concerned about Jaguar family company Napo Pharmaceuticals sponsored the "More Than a Diagnosis: A Quality of Life Survey for Individuals with... Read More
SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc . (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference , taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 1:15pm... Read More
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2024 /... Read More
SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's... Read More
FDA-approved Gelclair ® is company's third commercialized prescription product Susan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar... Read More
SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference , which takes place September 9-11, 2024. Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 26th... Read More
Company's Canalevia ® -CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month , a time devoted to raising awareness and... Read More
Click here to view interview video Paramount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair ® and results from independent, investigator-initiated trials of crofelemer for rare diseases SAN FRANCISCO, CA / ACCESSWIRE / September 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a new Innovators with Jane King video... Read More
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected... Read More
Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by... Read More
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected... Read More
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in... Read More
Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results Click here to register for investor webcast Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the quarter ended June 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / August 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday,... Read More
In 2022 breast cancer was the most common cancer in women in 157 countries out of 185, and lung cancer is the most common cancer worldwide. 1 Click here to register for webcast. Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi of crofelemer in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel... Read More
Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced , Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for... Read More
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have... Read More
New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected... Read More
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. Jaguar to host investor webcast Tuesday, July 23 rd at 8:30 AM Eastern to provide updates on company's cancer... Read More
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS... Read More
New patents issued for core rare disease target indications for crofelemer Napo has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with results expected in 2024 and 2025 SAN FRANCISCO, CA /... Read More
JAGX's securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that... Read More
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositis In honor of World Rainforest Day (June... Read More
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral... Read More
SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units (RSUs) to one new employee. These RSUs vest over one year starting from this new employee's date of hire. The RSUs for this new employee were granted as an inducement material to this new employee's acceptance of employment... Read More
The drug candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms Jaguar to receive percent of milestone payments and increasing royalties upon commercialization into the U.S. schizophrenia market, which is estimated to reach $8.06 billion by 2030 Jaguar to present May 30 at Lytham Partners... Read More
SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo's novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool... Read More
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea 18 million people in U.S. are living with a cancer diagnosis and more than 2 million people in U.S. are expected to be... Read More
Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio... Read More
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar planning to... Read More
Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate... Read More
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German... Read More
Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 14, 2024, at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.... Read More
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has established a new Investigational New Animal Drug (INAD) file with... Read More
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo... Read More
Jaguar planning to begin commercial launch of FDA-approved Gelclair ® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ” patient advocacy program at ONS Congress SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the... Read More
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair ® , a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine... Read More
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair ® , the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an exclusive... Read More
Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 9, 2024 (the "Special... Read More
Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") has... Read More
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium price SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today... Read More
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 million Top line results expected forthcoming for company's phase 3 OnTarget trial... Read More
Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide... Read More
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed a binding term sheet covering the exclusive license and commercialization agreement ("the Agreement") for Jaguar's novel plant-based, FDA-approved prescription drug... Read More
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the status of its listing with The Nasdaq Stock Market LLC ("Nasdaq"). "Jaguar requested a hearing to appeal a potential delisting of the Company's securities from Nasdaq, and I'm pleased to report that a hearing has been scheduled, " said Lisa Conte, Jaguar's president and... Read More
Canalevia ® -CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / February 15, 2024 / Jaguar Health, Inc.... Read More
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi ® to Direct Relief , a Santa Barbara, California-based humanitarian aid organization. Active in all 50 states and more than 80 countries, with a mission to improve the health and lives of people affected by poverty or... Read More
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both short bowel syndrome and microvillus inclusion disease SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2024 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has submitted an Orphan... Read More
Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD, depression & anxiety SAN FRANCISCO, CA / ACCESSWIRE / January 30, 2024 / Jaguar Health, Inc . (NASDAQ:JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences, Inc. (Magdalena), the... Read More
SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City, New Jersey and participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February... Read More
This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention and treatment of CTD Studies published in peer-reviewed journals and continuum of datapoints highlight the neglected and growing need for treatment of one of the most common and debilitating side effects of... Read More
SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 4, 2024, the Company granted 7,500 restricted stock units (RSUs) to one new employee. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. The RSUs for this new employee were granted as an... Read More
New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease - an ultrarare CDD - and short bowel syndrome (SBS) in the US, EU, and Middle East/North Africa regions, with results expected in 2024 SAN FRANCISCO, CA / ACCESSWIRE / January 4, 2024 / Napo Pharmaceuticals... Read More
Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track Cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected need for new therapies for cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / December 11, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health,... Read More
SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that a Multinational Association of Supportive Care in Cancer (MASCC) webinar titled "GI Toxicities from Cancer Therapies - Prevention and Management," taking place Monday, January 29, 2024 from 11:30 AM to 12:30 PM Eastern Standard Time, was made possible by an unrestricted... Read More
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound... Read More
Canalevia ® -CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA Crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / December 4, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the... Read More
Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference.... Read More
SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the company has not yet been provided with results from the company's GCP (Good Clinical Practice) vendors supporting Napo's pivotal Phase 3 OnTarget trial . The trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis of diarrhea in adult... Read More
Net revenue increased 5% in Q3 2023 versus Q2 2023 Top line results expected before Thanksgiving for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea REMINDER: Jaguar to host investor webcast Tuesday, November 14th at 8:30 a.m. Eastern regarding Q3 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 14,... Read More
SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective November 7, 2023, the Company granted 7,500 restricted stock units (RSUs) to one new employee. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. The RSUs for this new employee were granted as an... Read More
SAN FRANCISCO, CA / ACCESSWIRE / November 9, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound challenges... Read More
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on November 8, 2023 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC has granted Jaguar an additional 180-day grace period, through May 6, 2024, to regain compliance with the $1.00 bid price requirement for continued listing... Read More
Click here to register for November 14 investor webcast Company plans to file its Earnings Report on November 14, 2023 on Form 10-Q for the quarter ended September 30, 2023 REMINDER: Jaguar to host virtual educational webinar on rare intestinal failure diseases with leading gastroenterologists and nutrition experts November 8, 2023 from 1:00 PM to 2:30 PM Eastern; Click here to register for webinar SAN FRANCISCO, CA /... Read More
Click here to register for webinar SAN FRANCISCO, CA / ACCESSWIRE / November 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today issued a reminder that the company is hosting a virtual educational webinar with leading gastroenterologists and nutrition experts on intestinal failure associated with the rare diseases short bowel syndrome (SBS) and microvillus inclusion disease (MVID)... Read More
Quadri Pharma will cover 50% of the costs of development activity up to a capped dollar contribution Jaguar to host virtual educational webinar on intestinal failure with leading gastroenterologists and nutrition experts November 8 th from 1:00 PM to 2:30 PM EST; Click here to register for the webinar SAN FRANCISCO, CA / ACCESSWIRE / November 2, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family... Read More
New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2023 / Napo Pharmaceuticals (Napo), a... Read More
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Magdalena Biosciences, Inc. (Magdalena), the joint venture recently formed by Jaguar and Filament Health... Read More
Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentation SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting virtually at the Emerging Growth Conference on Wednesday, November 1, 2023 from... Read More
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications Magdalena launches corporate website SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Magdalena Biosciences, Inc. , the joint venture recently formed by... Read More
MVID, for which there are no approved drug treatments, is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea Crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for MVID, and the Company's Investigational New Drug application for... Read More
Mytesi ® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy Napo to host educational dinner for nurses about HIV-related diarrhea and Mytesi during conference SAN FRANCISCO, CA / ACCESSWIRE / October 18, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual... Read More
Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of... Read More
Canalevia ® -CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that it is exhibiting at the Veterinary Cancer Society (VCS) Annual Conference , which takes place October 12-14, 2023... Read More
Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023... Read More
Lip-syncing and singing contest on social media features opportunity to duet with Grammy Award-winner Jenn Colella and encourages open dialogue about chronic and surprise diarrhea Visit the contest social channels @surprisediarrheacontest on TikTok and/or Instagram to enter contest All entries will support donation to nonprofit organization dedicated to supporting HIV long-term survivors; winners will receive prize money,... Read More
SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2023 / In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced they were proud to provide fiscal support for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of... Read More
HealthStocksHub
Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications Import of coca leaves was authorized by the Peruvian Health Authority SAN FRANCISCO, CA / ACCESSWIRE / September 21, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that... Read More
Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with... Read More
New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE... Read More
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Jaguar intends to pursue a Tropical Disease Priority Review Voucher, under FDA's financial incentive program, to develop NP-300 for this indication SAN FRANCISCO, CA / ACCESSWIRE / September 12, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that it has... Read More
Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with... Read More
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 Dr. Brunke to present at the October 30-November 2, 2023 World Orphan Drug Congress in Barcelona and the November 6-8, 2023 BIO-Europe ®... Read More
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / August 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing... Read More
Napo Pharmaceuticals, a Jaguar family company, reported completion August 17 of last patient last visit for its pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 28, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's president, founder, and CEO, will present virtually at the Emerging Growth... Read More
Jaguar aims to leverage digital technologies including AI enhancement to help connect with investor communities SAN FRANCISCO, CA / ACCESSWIRE / August 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (GI) prescription medicines, today announced it has engaged B2i Digital to execute an innovative digital investor engagement and... Read More
Company on track to report top line data in late October 2023 SAN FRANCISCO, CA / ACCESSWIRE / August 17, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo's pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of diarrhea in adult cancer... Read More
Jaguar Health family company Napo Pharmaceuticals focuses on essential supportive care and management of neglected toxicities in multiple complicated disease states SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2023 / Napo Pharmaceuticals, Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral... Read More
Net revenue increased 36% in Q2 2023 versus Q1 2023 Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa... Read More
Click here to register for webcast Company plans to file its Earnings Report on August 14, 2023 on Form 10-Q for the quarter ended June 30, 2023 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, August 14, 2023 at 8:30 a.m. Eastern Daylight Time to review second-quarter 2023 financials and provide corporate... Read More
Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in event of exposure to cholera due to bioterrorism or advancement of cholera into US territories due to global warming Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Jaguar to present August 10th at Emerging Growth Conference; Individual and... Read More
MVID is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 8, 2023 / Napo Pharmaceuticals Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the activation by the U.S. Food and Drug Administration (FDA) of the... Read More
A significant proportion of patients undergoing cancer therapy experience diarrhea, which has the potential to cause dehydration and non-adherence to cancer treatment regimens Diarrhea was reported in 95% of neratinib-treated patients in randomized placebo-controlled trial SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") announced that the results of an... Read More
SAN FRANCISCO, CA / ACCESSWIRE / August 3, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting at an invitation-only lunch gathering of the Wall Street Wonders Investment Group in New York City at 1:30 p.m. EDT on Friday August 4, 2023. The Wall Street Wonders Investment Group is comprised of fund managers, money managers, retail brokers, family... Read More
Napo Medical Affairs Team Member, who is an HIV/Mytesi ® (Crofelemer) Patient, to Participate in Educational Panel SAN FRANCISCO, CA / ACCESSWIRE / August 2, 2023 / Jaguar Health (NASDAQ:JAGX) company Napo Pharmaceuticals (Napo) issued a reminder today that it will be participating in Pineapple Healthcare's Butt Stuff Brunch with Doctor Carlton - an educational drag show and food event about sexual health featuring guest... Read More
Napo Pharmaceuticals, a Jaguar Health company and the manufacturer of crofelemer, is supporting this physician-generated IND SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2023 / Jaguar Health (NASDAQ:JAGX) ("the Company") today announced the activation by the U.S. Food and Drug Administration (FDA) of a physician-requested Investigational New Drug (IND) application to evaluate crofelemer for treatment of uncontrolled diarrhea... Read More
Activities support sustainable supply of Jaguar's botanical drug crofelemer, the active ingredient in the company's FDA-approved human drug Mytesi ® and FDA conditionally approved animal drug Canalevia ® -CA1 SAN FRANCISCO, CA / ACCESSWIRE / July 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), in honor of World Nature Conservation Day, July 28 th , announced that Jaguar, together with its predecessor companies, and... Read More
Canalevia ® -CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA Crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar... Read More
Napo Medical Affairs Team Member, who is an HIV/Mytesi ® (Crofelemer) Patient, to Participate in Educational Panel SAN FRANCISCO, CA / ACCESSWIRE / July 25, 2023 / Jaguar Health (NASDAQ:JAGX) company Napo Pharmaceuticals (Napo) today announced that it will be participating in Pineapple Healthcare's Butt Stuff Brunch with Doctor Carlton - an educational drag show and food event about sexual health featuring guest speaker... Read More
Chimerix

COPYRIGHT ©2023 HEALTH STOCKS HUB